Home › Compound Library › Semax
Cognitive and neuroprotective
Semax: A Registered Medicine in One Country, a Research Peptide Everywhere Else
The short answer
Semax is a short peptide built from a fragment of ACTH, stripped of the hormonal activity and left with the effects on the brain. It has been a registered medicine in Russia for decades, used in stroke care, and the research behind that is mostly published in Russian journals. In July 2026 an FDA advisory committee recommended it for pharmacy compounding.
Questions people ask about Semax
Semax at a glance
| Also called | ACTH (4-10) Pro-Gly-Pro; N-acetyl semax is the acetylated version |
|---|---|
| What it is | A synthetic peptide: the ACTH (4-10) fragment with a Pro-Gly-Pro tail added for stability |
| Acts on | BDNF and NGF expression; melanocortin and dopaminergic signalling |
| Main system | Brain: attention, recovery after ischaemia, stress resilience |
| Evidence level | Registered and used clinically in Russia; animal and mechanistic work elsewhere |
| FDA status (Sept 2026) | Not approved. Recommended by an FDA advisory committee in July 2026 for the list of substances pharmacies may compound |
| In sport | Not named on the 2026 WADA prohibited list |
What is semax?
ACTH is the hormone that tells the adrenal glands to make cortisol. Researchers noticed decades ago that a middle fragment of it, amino acids 4 to 10, acted on the brain without carrying the hormonal job. Semax is that fragment with a three-amino-acid tail (Pro-Gly-Pro) attached to keep it from being broken down immediately.
The result is a peptide with effects on attention, memory and recovery after brain injury, and none of the cortisol activity of the parent hormone. It is given as a nasal spray in clinical use, which is unusual for a peptide and part of why it is discussed at all.
The Cognitive Advantage profiles it at pp. 115–119 and covers the acetylated version at pp. 130–133; Targeted Peptide Systems covers it at pp. 185–188.
How does semax work?
Neurotrophins are the main story. Semax raises expression of BDNF and NGF, the growth factors that maintain neurons and support the formation of new connections. Research in rat hippocampus and cortex measured that increase directly, and found it after cerebral ischaemia as well as at baseline (references 1, 2).
Beyond neurotrophins, it influences dopaminergic and serotonergic signalling and reduces markers of oxidative stress after ischaemia, which is the mechanism behind its clinical use in stroke care.
The Cognitive Advantage (pp. 66–68) places it among the compounds that work by supporting the brain’s own maintenance machinery rather than by stimulating it, which is a different category from the classic nootropics.
What does the research show?
Stroke is where the clinical work sits. Russian trials from the late 1990s onward reported benefit in the acute period of ischaemic stroke, with later work examining its use at different stages of recovery (reference 3). These studies are published in Russian journals and are generally small.
The mechanistic work is published internationally. The neurotrophin findings appear in international journals and reproduce (references 1, 2), so the mechanism behind the clinical use has support from well outside the programme that developed it.
Where the evidence stands. Decades of registered clinical use, a literature published largely in Russian, and mechanistic work confirmed internationally. A clinical history on one side and a described mechanism on the other is a stronger position than most compounds discussed as research peptides occupy.
Side effects and cautions
The safety record from Russian clinical use is quiet, which is meaningful given the length of that use and the fact that much of it has been in acutely ill patients. The most commonly reported effect is nasal irritation from the spray.
One thing the clinical record does not cover is continuous use by healthy people looking for a cognitive edge. That is a different population from the stroke patients in the trials, and a different pattern of use, so it is worth factoring into how long anyone plans to take anything.
The practical risk outside a clinical setting is the product. Material sold for research use is not made to medicine standards, so purity and identity depend entirely on the supplier.
Is semax legal or FDA approved?
Not FDA approved. On 23–24 July 2026 the FDA’s Pharmacy Compounding Advisory Committee recommended semax for the 503A bulks list, one of six peptides it recommended at that meeting (references 4, 5). That vote is a recommendation. It is not binding, and formal rulemaking has to follow before compounding pharmacies can use it.
It is a registered medicine in Russia, which is the source of the clinical experience behind it and has no bearing on its US status.
Sport: semax is not named on the 2026 WADA prohibited list. Check with your governing body, since lists are updated annually.
Semax vs selank, and where it sits among cognitive compounds
Semax is usually discussed alongside selank, a peptide from the same research group, and the two are often confused.
- vs selank: selank is derived from a fragment of tuftsin and is studied mainly for anxiety and stress. Semax is aimed at attention, recovery and neuroprotection. Same lineage, different targets.
- vs N-acetyl semax: the acetylated version is more stable and is often described as longer acting. The Cognitive Advantage covers it at pp. 130–133.
- vs the repair peptides: BPC-157 and TB-500 are structural compounds. Semax is not doing the same job and is not a substitute in a recovery protocol.
- vs epitalon: the other peptide from this research tradition recommended for compounding in July 2026, and aimed at a completely different system.
The Cognitive Advantage (pp. 64–68) is where the book sets out how it chooses between cognitive compounds rather than stacking them.
Risk, benefit, and the conversation this page is for
Semax reached the clinic on the strength of real trial work. It has been a registered medicine in Russia for decades, used in stroke care, and the studies behind that registration were published in Russian journals through the 1990s and 2000s. The mechanistic work on BDNF and NGF has been published internationally and reproduces. So the clinical use and the mechanism point the same way, from two different directions — which is more than most compounds in this library can say.
The regulatory picture is moving, and it is moving one compound at a time. In July 2026 an FDA advisory committee recommended six peptides, BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax, for the list of bulk substances compounding pharmacies may use. The same committee has turned peptides down and still does: ipamorelin and CJC-1295 sit in Category 2, barred from compounding. The distinction is the useful part. Each compound is being read on its own risk record rather than lumped under one verdict called unapproved.
The clinicians working with these compounds are not fringe, and their reasoning is comparative rather than enthusiastic. The approved options for chronic inflammation and slow-healing tissue carry burdens that are thoroughly documented: long-term anti-inflammatories on the gut and kidneys, repeated corticosteroid injections on connective tissue, glucose control and bone. Weighed against that, a compound with a quiet toxicology record and an incomplete efficacy record is a reasonable thing to discuss. It is not a reasonable thing to promise, and that is the line this page tries to hold.
Which is the point of the series. Nothing here is a recommendation to use semax. People misuse approved medicines and unapproved compounds alike, and that is neither the purpose nor the intent of this page. The point is a better conversation than the internet usually allows: with a clinician who knows your history, your labs and everything else you take, and who can help build a plan that fits you.
Semax: frequently asked questions
What is semax?
A synthetic peptide built from the ACTH (4-10) fragment with a Pro-Gly-Pro tail added for stability. It acts on the brain without the hormonal activity of the parent hormone.
What is semax used for?
In Russia, where it is a registered medicine, it has been used in stroke care. Outside that, it is discussed for attention, mental stamina and recovery, which are extrapolations from the clinical and animal work.
Is semax FDA approved?
No. In July 2026 an FDA advisory committee recommended adding it to the list of substances compounding pharmacies may use, which is a non-binding step and not an approval (references 4, 5).
How does semax work?
Primarily by raising BDNF and NGF, the growth factors that maintain neurons and support new connections. That increase has been measured directly in animal brain tissue (references 1, 2).
Semax vs selank: what is the difference?
Both came out of the Institute of Molecular Genetics at the Russian Academy of Sciences. Selank is studied mainly for anxiety; semax is aimed at attention, recovery and neuroprotection.
What is N-acetyl semax?
The acetylated version, more stable and generally described as longer acting. The Cognitive Advantage covers it at pp. 130-133.
What are semax’s side effects?
Nasal irritation from the spray is the most commonly reported. The safety record from Russian clinical use is quiet. That record covers treatment rather than continuous use by healthy people, which is worth knowing when deciding how long to use it.
Is semax banned in sport?
It is not named on the 2026 WADA prohibited list. Check with your sport’s governing body, as lists change each year.
Where Semax appears in our books
This page is the plain-language overview. The books go further: mechanism detail, evidence tiers, how Semax fits a full protocol, and the cautions that go with it. Page numbers refer to the print editions.
The Cognitive Advantage
Profile, Category 1 cognitive compounds · pp. 115-119
About the bookLook Inside
Books marked Look Inside include these exact pages in their free preview.
Related compounds
See how Semax fits a protocol
The free Protocol Builder maps the pathways a compound works on and shows what complements it for your goal, built from the same database as this library.
Open the Protocol BuilderSee the book seriesReferences
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54–60. View source
- Dmitrieva VG, Povarova OV, Skvortsova VI, et al. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2010;30(1):71–79. View source
- Gusev EI, Skvortsova VI, Miasoedov NF, et al. Effectiveness of semax in acute period of hemispheric ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26–34. View sourcePublished in Russian
- U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. View source
- National Community Pharmacists Association. FDA advisory committee nominates six peptides for pharmacies to compound. July 31, 2026. View source
- World Anti-Doping Agency. The 2026 Prohibited List. View source
How this page is maintained. Regulatory status and trial results change. We review this page against current sources and update it as new information becomes available; the date at the top shows the last review.
Educational information only, not medical advice. Semax is discussed here for education. Nothing on this page is a recommendation to use it or a dosing guide. Talk to a qualified clinician before starting, stopping or combining any compound.